Skip to main content
OpenTrials
Completed

NCT Number: NCT02763410

Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation

Safety during transfusions is a major issue in medical economics. Despite drastic quality control measures, transfusion is still a source of short, mid and long-term morbi-mortality. This can be explained to some extent by changes in the composition of the packed red blood cell (PRBC) supernatant during storage essentially with the appearance of immunologically active compounds possibly involved in organ dysfunction on the one hand and post-transfusion immunomodulation on the other hand. These phenomena impact upon outcomes for cardiac surgery patients.

In terms of organ dysfunction, kidney failure due to acute tubular necrosis and pulmonary failure are the 2 main issues. Following cardiac surgery, 11% of patients will present with transient renal dysfunction characterised by a 25% increase in serum creatinine levels and 3.5% require dialysis. The intensity of acute renal failure (ARF) is correlated to resuscitation : a 20% increase in serum creatinine levels 2 to 3 days after surgery significantly raises morbidity rates and a 50% increase raises the mortality rate to 10%.

The precise mechanisms governing post-transfusion immunomodulation have not yet to be defined. The appearance of soluble type I Human leukocytes Antigen (HLA) molecules (sHLA-I), the FAS ligand (FAS-L) or cluster designation 40 (CD40-L) in the supernatant of PRBCs along the storage of blood products may be involved in such phenomena. These molecules are capable of activating or triggering the death of innate or adaptive immunity cells, especially the Natural Killer (NK) cells.

Consequently the investigators propose to focus specifically on the detailed composition of transfused PRBC supernatants in order to identify the candidate molecules responsible for organ dysfunction or post-transfusion immunoparalysis. The investigators will combine a clinical approach based on the transcriptional analysis of renal tubular cells in transfused patients and an ex-vivo approach investigating the effect of the supernatant on immune cells and the Natural Killer cells of healthy volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Failure Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nantes

Nantes, 44093, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Non-emergency cardiac surgery under extracorporeal circulation (CEC) with cardioplegia:

And no indication of pre-surgical PRBC transfusion (priming excluded), And no indication of transfusion with fresh frozen plasma or pre-surgical platelet concentrate

Exclusion criteria

  • Heart and/or lung transplant surgery;
  • Emergency surgery to be performed within 24 hours;
  • Patient <18 years old;
  • Pregnant woman
  • Protected adult
  • Adult incapable of expressing his/her non-opposition
  • Opposition expressed by the patient on recording his/her data;
  • No French social security;
  • Patient who underwent a transfusion in the 3 months prior to surgery;
  • Surgery due to endocarditis or suspected endocarditis;
  • Myocardial infarction < 15 days;
  • Patient receiving inotropic or vasopressor prior to surgery;
  • Patient receiving immunosuppressant treatment;
  • Patient receiving corticosteroids for 21 days or more;
  • Seropositive patient known to be suffering from HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • Currently taking antibiotics (except permitted peri-surgical antibiotic prophylaxis );
  • History of advancing cancer;
  • Clearance < 40 ml/min/m2 according to the Modification of Diet in Renal Disease (MDRD) during the pre-surgical assessment;
  • Positive irregular antibody test warranting a cross-match prior to transfusion.
  • Patients with indwelling urinary catheter preoperatively
  • preoperative positive urine culture
  • Urinary tract infection <21 days before surgery
  • Background gesture on the upper or lower urinary tract

Exclusion criteria

analysis

  • In the renal insufficient group: Patient transfused plasma (s) Fresh Frozen (s) (PFCs) or concentrate (s) platelet (s) (CP) after the balance sheet T6 (6 hours after arrival in the ICU) and before the diagnosis of ARF,
  • strict anuric patient not to achieve a 50 ml urine sample at least
  • Reversal surgery requiring CEC before the 48th hour
  • Surgical Complication could explain the acute renal failure (IRA)

Treatment and study plan

PRBC transfusion

Other

Primary outcomes

  1. link between the composition of the PRBC supernatant and the onset of renal failure

    Time frame: 48 hours following surgery

Secondary outcomes

  1. Respiratory dysfunction in the ICU defined by a blood pressure of oxygen (PaO2)/inspired oxygen fraction (FiO2) ratio < 300 on at least one occasion

    Time frame: within 28 days

  2. Number of dialysis days

    Time frame: within 28 days

  3. Duration of stay

    Time frame: within 28 days

  4. Ventilation period (in hours);

    Time frame: within 28 days

  5. ICU-acquired infection

    Time frame: within 28 days

  6. Status at discharge from ICU: Dead/alive

    Time frame: day 28

  7. Study of transfusion-related accidents recorded in ICU

    Time frame: within 28 days

  8. Hospital admission, regardless of cause

    Time frame: 1 year

  9. Hospital admission due to infection

    Time frame: 1 year

  10. Diagnosis of cancer

    Time frame: 1 year

  11. Clinical course of pre-existing cancer

    Time frame: 1 year

  12. Survival

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • Etablissement Français du Sang

Registry information

Official study title

Impact of the Composition of the Packed Red Blood Cell Supernatant on Renal Dysfunction and Post-transfusion Immunomodulation

Acronym: TRANSNEPHRON

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
May 5, 2016
Registry last updated
Apr 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.